1. Foulkes, WD . Inherited susceptibility to common cancers. N Engl J Med 2008; 359: 2143–2153.
Google Scholar | Crossref | Medline | ISI2. Venkitaraman, AR . Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 2001; 114: 3591–3598.
Google Scholar | Crossref | Medline3. Isakoff, SJ, Mayer, EL, He, L, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015; 33: 1902–1909.
Google Scholar | Crossref | Medline | ISI4. Tutt, A, Tovey, H, Cheang, MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med 2018; 24: 628–637.
Google Scholar5. Robson, M, Im, SA, Senkus, E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377: 523–533.
Google Scholar | Crossref | Medline6. Litton, JK, Rugo, HS, Ettl, J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018; 379: 753–763.
Google Scholar | Crossref | Medline7. Friedlaender, A, Vuilleumier, A, Viassolo, V, et al. BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. Breast Cancer Res Treat 2019; 174: 775–783.
Google Scholar | Crossref | Medline8. Lakhani, SR, Van De Vijver, MJ, Jacquemier, J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310–2318.
Google Scholar | Crossref | Medline | ISI9. Atchley, DP, Albarracin, CT, Lopez, A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008; 26: 4282–4288.
Google Scholar | Crossref | Medline | ISI10. Mavaddat, N, Barrowdale, D, Andrulis, IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21: 134–147.
Google Scholar | Crossref | Medline | ISI11. National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology (NCCN Guidelines®). Breast cancer, version 5, 2021, https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (2021, accessed 1 July 2021).
Google Scholar12. Schmid, P, Adams, S, Rugo, HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379: 2108–2121.
Google Scholar | Crossref | Medline13. Cortes, J, Cescon, DW, Rugo, HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020; 396: 1817–1828.
Google Scholar | Crossref | Medline14. National Cancer Institute . Surveillance, Epidemiology, and End Results Program. Cancer stat facts: female breast cancer subtypes, https://seer.cancer.gov/statfacts/html/breast-subtypes.html (accessed 1 July 2021).
Google Scholar15. Donawho, CK, Luo, Y, Luo, Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728–2737.
Google Scholar | Crossref | Medline | ISI16. Appleman, LJ, Beumer, JH, Jiang, Y, et al. A phase I study of veliparib (ABT-888) in combination with carboplatin and paclitaxel in advanced solid malignancies. J Clin Oncol 2012; 30: abstract 3049.
Google Scholar | Crossref17. Somlo, G, Frankel, PH, Arun, BK, et al. Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium trial NCT01149083. Clin Cancer Res 2017; 23: 4066–4076.
Google Scholar | Crossref | Medline18. Han, HS, Diéras, V, Robson, M, et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol 2018; 29: 154–161.
Google Scholar | Crossref | Medline19. Diéras, V, Han, HS, Kaufman, B, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21: 1269–1282.
Google Scholar | Crossref | Medline20. Tong, CWS, Wu, M, Cho, WCS, et al. Recent advances in the treatment of breast cancer. Front Oncol 2018; 8: 227.
Google Scholar | Crossref | Medline21. Emens, LA, Molinero, L, Loi, S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst 2021; 113: 1005–1016.
Google Scholar | Crossref | Medline